Prevalence of Metabolic Dysfunction Associated Steatotic Liver Disease (MASLD) in Young Type 2 Diabetes Mellitus Patients & Its Association with Insulin Resistance

Authors

  • Khwaja Saifullah Zafar Professor, Department of Medicine, Jawaharlal Nehru Medical College, Aligarh Muslim University, Aligarh, India Author
  • Syed Hasan Amir Associate Professor, Department of Medicine, Jawaharlal Nehru Medical College, Aligarh Muslim University, Aligarh, India Author
  • Hamid Ashraf Professor, Department of Medicine, Jawaharlal Nehru Medical College, Aligarh Muslim University, Aligarh, India Author
  • Anup Sharma Third Year, Junior Resident, Department of Medicine, Jawaharlal Nehru Medical College, Aligarh Muslim University, Aligarh, India Author

Keywords:

Metabolic dysfunction-associated steatotic liver disease, Type 2 Diabetes Mellitus, Insulin resistance, HOMA-IR, FibroScan, Hepatic fibrosis

Abstract

Introduction: Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common chronic liver disease worldwide. Young-onset Type 2 Diabetes Mellitus (T2DM) increases the risk of MASLD due to insulin resistance, obesity, and adverse metabolic profiles, predisposing individuals to early hepatic steatosis and fibrosis.

Aim & Objective: This study aimed to determine the prevalence of MASLD among young adults with T2DM and to evaluate its association with insulin resistance and other metabolic risk factors.

Materials and Methods: A hospital-based cross-sectional study included 92 adults aged 18–40 years with T2DM. Clinical, anthropometric, biochemical, and glycaemic parameters were assessed. Insulin resistance was evaluated using HOMA-IR, while hepatic steatosis and fibrosis were assessed by FibroScan (CAP and LSM). Statistical analyses included group comparisons, correlations, logistic regression, and ROC analysis.

Results: MASLD was identified in 51 participants, yielding an overall prevalence of 55.4%. Insulin resistance (HOMA-IR ≥1.7) was present in 73.9% of the study population and was significantly more frequent among participants with MASLD than those without the disease (64.7% vs. 20.0%, p<0.001). Individuals with MASLD demonstrated significantly higher HOMA-IR values, fasting insulin levels, HbA1c, fasting and postprandial blood glucose, body mass index, waist circumference, triglycerides, LDL cholesterol, and liver enzyme levels. FibroScan assessment revealed evidence of advanced fibrosis in 26.1% of participants. HOMA-IR showed good diagnostic performance for predicting MASLD (AUC = 0.842), with an optimal cut-off value of 3.15.

Conclusion: MASLD is common in young adults with T2D M and is strongly linked to insulin resistance, obesity, poor glycaemic control, dyslipidaemia, and fibrosis, highlighting the need for routine screening and early metabolic interventions.

REFERENCES

  1. Zhou Y, Chen Y, Tang Y, Zhang S, Zhuang Z, Ni QJD, et al. Rising tide: the growing global burden and inequalities of early-onset type 2 diabetes among youths aged 15–34 years (1990–2021). 2025;17(1):1-14. https://doi.org/10.1186/s13098-025-01673-0
  2. Zhang K, Ma Y, Luo Y, Song Y, Xiong G, Ma Y, et al. Metabolic diseases and healthy aging: identifying environmental and behavioral risk factors and promoting public health. 2023;11:1-10. https://doi.org/10.3389/fpubh.2023.1253506
  3. Rodriquez IM, O’Sullivan KL. Youth-onset type 2 diabetes: burden of complications and socioeconomic cost. Clin Diabetes Res. 2023;23(5):59-67. https://doi.org/10.1007/s11892-023-01501-7
  4. Younossi ZM, Golabi P, Paik JM, Henry A, Van Dongen C, Henry L. The global epidemiology of nonalcoholic fatty liver disease (MASLD) and nonalcoholic steatohepatitis (MASH): a systematic review. Hepatology. 2023;77(4):1335-1347. https://doi.org/10.1097/hep.0000000000000004
  5. Wang J, Du J, Wang M, Jin M, Tang Z, Mao Y. Global, regional, and national burden of MASLD in youths and young adults aged 15-39 years, 1990-2021, its attributable risk factors, and projections to 2035: a systematic analysis of the Global Burden of Disease Study 2021. Front Nutr. 2025;12:1-15. https://doi.org/10.2139/ssrn.4968223
  6. Grander C, Grabherr F, Tilg H. Non-alcoholic fatty liver disease: pathophysiological concepts and treatment options. Cardiovasc Res. 2023;119(9):1787-1798. https://doi.org/10.1093/cvr/cvad095
  7. Strati M, Moustaki M, Psaltopoulou T, Vryonidou A, Paschou SA. Early onset type 2 diabetes mellitus: an update. Endocrine. 2024;85(3):965-978. https://doi.org/10.1007/s12020-024-03772-w
  8. Dharmalingam M, Yamasandhi PG. Nonalcoholic fatty liver disease and type 2 diabetes mellitus. Indian J Endocrinol Metab. 2018;22(3):421-428. https://doi.org/10.4103/ijem.ijem_585_17
  9. Marušić M, Paić M, Knobloch M, Liberati Pršo AM. MASLD, insulin resistance, and diabetes mellitus type 2. Can J Gastroenterol Hepatol. 2021;2021:1-9. https://doi.org/10.1155/2021/6613827
  10. Finelli C, Tarantino G. What is the role of adiponectin in obesity related non-alcoholic fatty liver disease? World J Gastroenterol. 2013;19(6):802-812. https://doi.org/10.3748/wjg.v19.i6.802
  11. Wang M, Wuyun Q, Lian D, Xu G, Zhu G, Zhang N. Global, regional, and national burden of nonalcoholic fatty liver disease (MASLD) among people aged 15 to 49 years from 1990 to 2021, with projections to 2050: a systematic analysis based on the 2021 global burden of disease study. Medicine (Baltimore). 2025;104(37):1-13. https://doi.org/10.1097/md.0000000000044527
  12. Ciardullo S, Vergani M, Perseghin G. Nonalcoholic fatty liver disease in patients with type 2 diabetes: screening, diagnosis, and treatment. J Clin Med. 2023;12(17):1-16. https://doi.org/10.3390/jcm12175597
  13. Abdelhameed F, Kite C, Lagojda L, Dallaway A, Chatha KK, Chaggar SS, et al. Non-invasive scores and serum biomarkers for fatty liver in the era of metabolic dysfunction-associated steatotic liver disease (MASLD): a comprehensive review from MASLD to MAFLD and MASLD. Curr Obes Rep. 2024;13(3):510-531. https://doi.org/10.1007/s13679-024-00574-z
  14. Mu W, Cheng XF, Liu Y, Lv QZ, Liu GL, Zhang JG, et al. Potential nexus of non-alcoholic fatty liver disease and type 2 diabetes mellitus: insulin resistance between hepatic and peripheral tissues. Front Pharmacol. 2019;9:1-10. https://doi.org/10.3389/fphar.2018.01566
  15. Tacke F, Horn P, Wong VW-S, Ratziu V, Bugianesi E, Francque S, et al. EASL–EASD–EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). J Hepatol. 2024;81(3):492-542. https://doi.org/10.1016/j.jhep.2024.04.031
  16. Misra S, Ke C, Srinivasan S, Goyal A, Nyriyenda MJ, Florez JC, et al. Current insights and emerging trends in early-onset type 2 diabetes. Lancet Diabetes Endocrinol. 2023;11(10):768-782. https://doi.org/10.1016/s2213-8587(23)00225-5
  17. Tanase DM, Gosav EM, Costea CF, Ciocoiu M, Lacatusu CM, Maranduca MA, et al. The intricate relationship between type 2 diabetes mellitus (T2DM), insulin resistance (IR), and nonalcoholic fatty liver disease (MASLD). J Diabetes Res. 2020;2020:1-16. https://doi.org/10.1155/2020/3920196
  18. Shil KK, Hasan M, Sultana N, Salam SBA, Mostafa SN, Hasanat MA. High prevalence of fatty liver in Bangladeshi adolescents and young adults with type 2 diabetes: key predictors and screening recommendations. Diabetes Metab Syndr Obes. 2025;18:2019-2027. https://doi.org/10.2147/dmso.s520806
  19. Hu C, Cioana M, Saini A, Ragganandan S, Deng J, Nadarajah A, et al. The prevalence of non-alcoholic fatty liver disease in pediatric type 2 diabetes: a systematic review and meta-analysis. Front Adolesc Med. 2024;2:1-18. https://doi.org/10.3389/fradm.2024.1303375
  20. Liu R, Liu R, Liu M, Tian Y, Liu J, Wang Y, et al. The inflammatory index and cytokines are associated with non-alcoholic fatty liver disease in type 2 diabetes mellitus. Front Med (Lausanne). 2025;12:1-15. https://doi.org/10.3389/fmed.2025.1659998
  21. Khan F, Dsouza S, Khamis AH, Abdul F, Farooqi MH, Sulaiman F, et al. Noninvasive assessment of the severity of liver fibrosis in MASLD patients with long-standing type 2 diabetes. J Gen Intern Med. 2025;40(10):2309-2318. https://doi.org/10.1007/s11606-025-09348-2
  22. Tang XX, Wu R, Chen JH, Wang FL, Zhao SL, Lu J, et al. Association between HOMA-IR and metabolic dysfunction-associated steatohepatitis in US adults with MASLD. Metab Open. 2025;1-11.
  23. Beyazal Polat H, Beyazal M, Arpa M, Kızılkaya B, Ayaz T, Gündoğdu ÖL, et al. Exploring the prevalence and risk factors of MASLD in patients with newly diagnosed diabetes mellitus: a comprehensive investigation. J Clin Med. 2025;14(10):1-11. https://doi.org/10.3390/jcm14103513
  24. Zhao H, Ji B, Wang X, Shi S, Sheng J, Ma X, et al. Association between SPISE and MASLD in patients with type 2 diabetes. Front Med (Lausanne). 2025;12:1-10.
  25. Zhao Y, Hu D, Cheng J, Cao H, Wang X, He J, et al. Personalized MASLD and liver fibrosis risk assessment for adults: glycemic status determines optimal choice of non-invasive indices. Diabetol Metab Syndr. 2025;17(1):1-13. https://doi.org/10.1186/s13098-025-02069-w
  26. Ying Y, Ji Y, Ju R, Chen J, Chen M. Association between the triglyceride-glucose index and liver fibrosis in adults with metabolism-related fatty liver disease in the United States: a cross-sectional study of NHANES 2017-2020. BMC Gastroenterol. 2025;25(1):1-10. https://doi.org/10.1186/s12876-024-03579-z

Downloads

Published

2026-09-19

Issue

Vol. 3 No. Issue 1 (2026)

Section

Articles

How to Cite

Prevalence of Metabolic Dysfunction Associated Steatotic Liver Disease (MASLD) in Young Type 2 Diabetes Mellitus Patients & Its Association with Insulin Resistance. (2026). Journal of Surgical Research and Reviews (ISSN: 3041-4857) , 3(Issue 1), 1-11. https://www.internationalmedicalpublishing.com/index.php/JSRR/article/view/331